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Palladium-mediated	in	situ	synthesis	of	an	anticancer	agent		
Eugenio	Indrigo,†a	Jessica	Clavadetscher,†a	Sunay	V.	Chankeshwara,a	Annamaria	Lilienkampf,a	and	
Mark	Bradley*a	
	
As	 a	 novel	 prodrug	 activation	 strategy	 Pd(0)	 nanoparticles		
entrapped	within	a	modular	polymeric	support	were	used,	in	a	cell	
culture	 system,	 to	 synthesise	 the	 anticancer	 agent	 PP-121	 from	
two	non-toxic	precursors,	 thereby	 inducing	 cell	death	 in	 the	 first	
example	of	in	situ	mediated	drug	synthesis.	
Bioorthogonal	 chemistries	 that	 can	 be	 carried	 out	 within	 a	
biological	 system	 without	 affecting	 normal	 cellular	 function	
have	revolutionized	the	analysis	of	biological	processes	in	their	
native	environment.1	Classical	examples	include	the	Staudinger	
ligation,2	strain-promoted	azide–alkyne	cycloaddition,3	and	the	
inverse-electron	 demand	 Diels	 Alder	 reaction	 of	 tetrazines.4	
Recently,	bioorthogonal	 reactions	using	 transition	metals	 (Rh,	
Au	 and	 Pd)	 have	 begun	 to	 be	 successfully	 applied	 in	 a	
biological	setting.5–9	Modifications	of	proteins	using	genetically	
encoded	 halogenated	 phenylalanines	 have	 for	 example	
enabled	 in	 vitro	 labelling	 of	 proteins	 via	 palladium-mediated	
coupling	 to	 boronic	 acid	 tags,10	 thereby	 allowing	 the	 non-
intrusive	 and	 real-time	 study	 of	 proteins11,12	 and	
carbohydrates13	 in	 bacteria.	 Another	 approach	 has	 been	 the	
application	 of	 palladium	 nanoparticle	 catalysts	 with	
allylcarbamate	 cleavage	 of	 both	 caged	 fluorophores	 and	 pro-
drugs	 (e.g.	 allylcarbamate-amsacrine),	 as	 well	 as	 a	 Suzuki-
Miyaura	 cross-coupling	 reaction	 inside	 mammalian	 cells.14	
Palladium-mediated	 transformations	have	 since	been	used	 to	
selectively	activate	proteins	and	other	prodrugs.	Chen	showed	
the	 activation	 of	 the	 enzyme	 phosphothreonine	 lyase	 (Ospf)	
based	on	decaging	of	a	propargyloxycarbonyl	(Proc)	protected	
catalytic	 lysine	 residues	 with	 homogeneous	 palladium	
catalysts,15	while	Weiss	demonstrated	that	the	anticancer	drug	
5-fluorouracil	could	be	generated	by	the	 in	situ	 (extracellular)	
decaging	of	a	propargyl	protected	prodrug.16		
	
Fig.	1.	 Synthesis	and	characterization	of	a	modular	 support	 functionalized	with	
Pd(0)	nanoparticles.	(a)	Synthesis	of	the	supported	Pd	catalyst;	(b)	TEM	analysis	
showing	 the	 homogeneous	 distribution	 of	 palladium	 nanoparticles	 throughout	
the	support,	with	an	average	particle	size	of	9.2	±	1.5	nm	(scale	bar	100	nm)	and	
a	Pd	content	of	0.24	±	0.08	µmol/mg	(ICP-OES,	n	=	9);	(c)	The	modular	supports	
(9.0	×	7.5	mm)	before	(left)	and	after	(right)	functionalization.17	
Here,	 the	 scope	 of	 palladium-mediated	 chemistry	 in	 a	
biological	environment	was	extended	to	in	situ	drug	synthesis,	
with	C–C	bond	 formation	via	 a	 Suzuki-Miyaura	cross-coupling	
demonstrated	 with	 the	 activation	 of	 a	 quenched	 bis-iodo-
BODIPY	scaffold	and	the	synthesis	of	the	anticancer	agent	PP-
121	from	two	coupling	partners.18		
	 Loading	an	active	metal	onto	a	solid	support	 is	a	common	
method	 to	 generate	 heterogeneous	 catalysts.19,20	 We	 have	
previously	 reported	 the	 entrapment	 of	 catalytically	 active,	
biologically	 compatible	 palladium(0)	 nanoparticles	 into	
polymers14,21–23	 with	 the	 generation	 of	 	 modular	 sintered	
aminomethyl	 polystyrene	 resin	 beads17,24	 in	 which	
nanoparticles	 of	 palladium	 are	 trapped	 within	 a	 physical	
polymer	framework	(Fig.	1).	
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	 Here,	 the	 catalytic	 activity	 of	 these	 modular	 Pd	 catalysts	
was	 confirmed	 by	 the	 decaging	 of	 bis-propargyloxycarbonyl	
(Proc)	rhodamine	110	1	 (Fig.	2a)	 in	phosphate	buffered	saline	
(PBS),	 5%	 fetal	 bovine	 serum	 (FBS),	 and	 PC-3	 (prostate	
adenocarcinoma)	 cell	 lysate.5,14,25,26	 The	 addition	 of	 the	 Pd	
catalyst	to	a	solution	of	1	(20	μM)	resulted	in	the	generation	of	
2	with	a	>500-fold	increase	in	fluorescence	in	PBS,	and	a	115-
fold	 and	 46-fold	 increase	 in	 cell	 lysate	 and	 in	 5	 %	 FBS,	
respectively	 (Supporting	 Fig.	 S1).	 The	 catalyst	 also	 decaged	1	
(20	 μM,	 18	 h	 incubation)	 in	 a	 cell-based	 assay,	 resulting	 in	
labelling	 of	 PC-3	 cells	 (Supporting	 Fig.	 S2	 and	 S3).	 To	
investigate	 the	 catalytic	 activity	 in	 a	 Suzuki-Miyaura	 cross-
coupling	 reaction,	 bis-iodo-1,3,5,7,8-pentamethyl-BODIPY	 3	
was	 reacted	 with	 2-thienyl	 and	 4-phenyl	 boronic	 acids	 (Fig.	
2b).	 Bis-iodo	 BODIPY	 3	 is	 non-fluorescent	 due	 to	 the	 heavy	
atom	 quenching	 effect,27	 but	 becomes	 fluorescently	
unquenched	following	cross-coupling	chemistry	with	2-thienyl	
or	4-phenyl	boronic	acids,	which	gives	 the	bis-thienyl	BODIPY		
4	(λEx/Em	520/574	nm)	and	bis-phenyl	BODIPY	5	(λEx/Em	518/552	
nm)	 (Supporting	 Fig.	 S4)	 with	 14	 and	 31-fold	 increases	 in	
fluorescence,	 respectively.	 The	 coupling	 reaction	 between	 2-
thienyl	and	4-phenyl	boronic	acid	with	bis-iodo	BODIPY	3	in	the	
presence	of	the	Pd	catalyst	in	cell	lysate	and	in	5%	FBS	resulted	
in	 a	 5.6	 and	1.2-fold	 increase	 in	 fluorescence	 for	4	 and	 a	 2.5	
and	3.3-fold	increase	for	5,	respectively	(pure	samples	of	4	and	
5	in	cell	lysate	and	5	%	FBS	gave	14	and	15-fold,	and	3	and	20-
fold	 increase,	 respectively)	 (Supporting	 Fig.	 S5),	 with	 the	 cell	
lysate	 influencing	 the	 fluorescence	of	5,	but	not	4.	 A	modest	
increase	 in	 fluorescence	 (<	1.5-fold)	was	also	observed	 in	 the	
absence	of	a	boronic	acid	due	to	a	partial	de-iodination	of	the	
BODIPY	 3.28	 However,	 the	 emission	 maximum	 of	 the	 de-
iodinated	 product	 (1,3,5,7,8-pentamethyl-BODIPY)	 is	 520	 nm	
compared	to	 the	>540	nm	for	both	cross-coupling	products	4	
and	 5	 (Supporting	 Fig.	 S6),	 thus	 allowing	 spectral	 resolution.	
PC-3	cells	were	 incubated	with	bis-iodinated	BODIPY	3	and	2-
thienyl	 boronic	 acid	 or	 4-phenyl	 boronic	 in	 the	 presence	 of	
catalyst	 and	 analyzed	 by	 flow	 cytometry	 and	 fluorescence	
microscopy	 (Supporting	 Fig.	 S7	 and	 S8).	 A	 shift	 of	 the	 cell	
population	 towards	 higher	 fluorescence	 intensity	 (42	 %)	 was	
observed	when	 incubating	cells	with	3,	 2-thienyl	boronic	acid	
and	catalyst	compared	to	control	cells	incubated	without	Pd	(8	
%),	indicating	the	in	situ	formation	of	4	(Fig.	2c).	Fluorescence	
microscopy	 verified	 the	 presence	 of	 intracellular	 4	 with	 an	
increase	in	fluorescence	compared	to	cells	treated	only	with	3	
and	2-thienyl	boronic	acid	(Fig.	2d).			
	 The	 Pd	 mediated	 cross-coupling	 reaction	 was	 applied	 to	
the	 in	 situ	 synthesis	 of	 the	 cytotoxic	 agent	 PP-121	 10.	 PP-
12118,29	 is	 known	 to	 suppress	 anaplastic	 thyroid	 carcinoma	
tumor	 growth	 by	 inhibition	 of	 mTOR	 (a	 member	 of	 the	
phosphatidylinositol-3-OH	 kinase	 (PI(3)K)	 family)30	 and	
tyrosine	 kinases	 (VEGF	 receptor).18	 Retrosynthetically,	10	 can	
be	formed	from	iodopyrazole	818	and	boronic	ester	9	(Fig.	3a),	
and	 incubating	8	 and	9	 in	 the	 presence	 of	 Pd	 catalyst	 under	
aqueous	conditions	gave	a	62	%	yield	of	10	in	72	h	(Fig.	3b).	
	
	
	
Fig.	2.	Fluorescent	“switch-on”	via	Pd	mediated	synthesis.	 (a)	Cleavage	of	Proc-
rhodamine	110	1	to	give	fluorescent	rhodamine	110	2.	(b)	Suzuki-Miyaura	cross-
coupling	 of	 the	 bis-aryl	 BODIPY	 dyes	 (4	 and	 5):	 Pd	mediated	 synthesis	 of	 bis-
thienyl	 BODIPY	 with	 PC-3	 cells.	 PC-3	 cells	 incubated	 with	 compound	 3	 in	 the	
presence	 of	 the	 Pd	 catalyst	 and	 2-thienyl	 boronic	 acid.	 (c)	 Flow	 cytometry	
analysis:	 Left	 panel:	 untreated	 cells;	middle	 panel:	 control	 cells	 treated	with	3	
and	2-thienyl	boronic	acid;	right	panel:	cell	treated	with	3,	2-thienyl	boronic	acid	
and	 Pd	 catalyst.	 (D)	 Cells	 were	 stained	 with	 CellMask™	 Deep	 Red	 (plasma	
membrane	 stain),	 fixed	 with	 paraformaldehyde,	 incubated	 with	 DAPI	 (nuclei	
stain)	and	imaged	by	fluorescence	microscopy:	(i)	without	Pd,	(ii)	with	Pd.	Panels	
show	from	left	to	right:	cell	nucleus	(blue)	and	synthesized	compound	4	(yellow;	
cell	 nucleus	 (blue)	 and	 cell	 membrane	 (red);	 and	 merged	 images	 (orange	
indicates	 co-localization	 of	 synthesized	 compound	4	 within	 cells).	 Scale	 bar	 20	
µm.	
PP-121	exhibits	 high	 cytotoxicity	on	PC-3	 cells,	which	express	
high	 levels	of	the	VEGF	receptor	and	are	susceptible	to	kinase	
inhibitors,	 with	 <50	 %	 cell	 viability	 at	 0.4	 µM	 (Fig.	 3c	 and	
Supporting	Fig.	S9).	The	toxicity	of	the	PP-121	precursors	8	and	
9	 were	 evaluated	 on	 PC-3	 cells	 to	 establish	 the	 ideal	
concentration	 range	 that	 could	 be	 used	 in	 the	 in	 situ	 cross-
coupling	 reactions.	 Azaindole	 boronic	 ester	 9	 showed	
negligible	toxicity	up	to	10	µM,	while	 iodo-pyrazole	8	showed	
no	 toxicity	 below	 4	 µM	 (Fig.	 3c).	 The	 cross-coupling	 reaction	
(0.5	μmol	Pd)	was	performed	in	the	extracellular	space	of	PC-3	
cells	 by	 incubating	8	 (2	 µM)	 and	9	 (10	µM)	 for	 5	 days	 in	 cell	
culture,	 with	 cell	 viability	 decreasing	 by	 50	 %	 under	 these	
conditions	 (Fig.	 3d).	 Since	 PP-121	 induces	 apoptosis,18	 the	
extent	of	apoptosis	upon	Pd	mediated	 in	situ	synthesis	of	PP-
121	on	PC-3	cells	after	24	h	was	evaluated	via	double	staining	
with	 the	 apoptosis	 marker	 annexin	 V-FITC	 and	 propidium	
iodide	(PI).	
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Fig.	3.	Bioorthogonal	in	situ	synthesis	and	evaluation	of	the	anticancer	agent	PP-
121	 10	mediated	 by	 Pd(0):	 (a)	 Cross-coupling	 of	 iodopyrazole	 8	 (2	 μM)	 with	
boronic	ester	9	(10	μM);	(b)	Formation	of	10	monitored	by	HPLC	with	detection	
at	254	nm	(conversion	 is	 calculated	based	on	 the	 integration	of	 the	peaks	of	8	
and	10);	(c)	Cytotoxicity	of	8,	9,	and	10	on	PC-3	cells.	PC-3	cells	were	incubated	
with	0–10	μM	of	8,	9,	 and	10	 for	 72	h	 after	which	 cell	 viability	was	measured	
(MTT	assay,	n	=	3).	(d)	PC-3	cells	were	incubated	with	8	(2	μM)	and	9	(10	μM)	in	
the	 presence	 of	 Pd	 (0.5	 μmol)	 for	 3	 and	 5	 days,	 after	 which	 cell	 viability	 was	
measured	(MTT	assay,	n	=	3).	The	data	represent	the	mean	±	S.D.	***	P<0.001	by	
one-way	 ANOVA	 with	 Dunnett	 post-test,	 compared	 with	 the	 control	 group	
treated	without	the	Pd.	 (e):	PC-3	cells	were	 incubated	with	8	 (2	μM)	and	9	 (10	
μM)	in	absence	(i)	and	in	presence	(ii)	of	Pd	(0.5	μmol)	for	24	h	and	stained	with	
Annexin-V/FITC	(X-axis)	and	PI	(Y-axis),	followed	by	flow	cytometry	analysis.	Early	
apoptotic	cells	are	located	in	the	bottom	right	quadrant.		
Treatment	 of	 PC-3	 cells	 with	 precursors	 8	 and	 9	 or	 the	 Pd	
catalyst	 (Supporting	 Fig.	 S11)	 did	 not	 show	 any	 increase	 in	
annexin-V	 labelling,	 compared	 to	 untreated	 cells.	 However,	
early	 apoptosis	 was	 evident	 in	 cells	 treated	 with	 the	 two	
precursors	in	the	presence	of	the	catalyst,	as	indicated	by	a	36	
%	shift	in	the	cell	population	towards	higher	FITC	fluorescence	
intensity	(Fig.	3e).	
	 In	 conclusion,	 we	 have	 demonstrated	 the	 ability	 of	 a	
biologically	 inert	 catalyst	 to	mediate	 cross-coupling	 reactions	
in	a	biological	cell	culture	setting.	This	was	established	by	the	
in	 situ	 synthesis	 of	 a	 BODIPY	 dye	 via	 Suzuki-Miyaura	 cross-
coupling	with	 two	 aryl	 boronic	 acids,	 resulting	 in	 fluorescent	
labelling	 of	 mammalian	 cells.	 The	 concept	 was	 successfully	
applied	to	the	in	situ	synthesis	of	the	anticancer	agent	PP-121	
through	 Suzuki-Miyaura	 cross-coupling	 of	 two	 non-toxic	
precursors,	 which	 induced	 localized	 cytotoxicity	 and	 early	
apoptosis	 on	 PC-3	 cancer	 cells.	 The	 range	 of	 therapeutic	
agents	 containing	 diaryl	 bonds	 provides	 a	 good	 basis	 for	 the	
applicability	 of	 this	 novel	 strategy	 of	 forming	 a	 cytotoxic	
compound	in	situ	via	cross-coupling	of	two	inactive	precursors	
and	opens	doors	to	new	methods	of	prodrug	activation.	
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